Venus Remedies Limited (NSE:VENUSREM) informed the exchanges on 21 August 2026 that its members approved alterations to the Memorandum of Association and Articles of Association at the Annual General Meeting held on 20 August 2026, following prior communications dated 26 May 2026 and 20 July 2026.
Key Highlights
- Members of Venus Remedies Limited approved the alteration of the MOA and AOA at the AGM held on 20 August 2026, as disclosed under Regulation 30 of SEBI LODR.
- The revised MOA aligns Clause III(A) with the Companies Act, 2013, updating the Object Clause to reflect current business practices and proposed activities in pharmaceuticals and allied sectors.
- The company adopted a new set of Articles of Association as per Table-F of Schedule I of the Companies Act, 2013, replacing the existing AOA.
- The principal business activities of the company remain unchanged, with operations continuing in the pharmaceutical sector across India and international markets including Germany.
About the Company
Venus Remedies Limited (NSE:VENUSREM) is a Panchkula, Haryana-based pharmaceutical company incorporated in 1989 (CIN: L24232CH1989PLC009705). It manufactures active pharmaceutical ingredients, formulations, and specialty injectable products, and operates manufacturing units across India along with an international subsidiary, Venus Pharma GmbH, located in Werne, Germany. Its products serve hospital and critical-care segments across multiple geographies.
Announcement in Detail
The company filed its disclosure on 21 August 2026 under Regulation 30 and other applicable provisions of SEBI LODR. At the AGM on 20 August 2026, members approved two distinct changes: first, the adoption of a revised Memorandum of Association aligned with Table-A of Schedule I of the Companies Act, 2013; and second, the adoption of a new Articles of Association per Table-F of the same Schedule.
The revised Clause III(A) of the MOA now covers a broad range of pharmaceutical and allied activities, including biologics, biosimilars, vaccines, cell and gene therapy products, medical devices, nutraceuticals, and digital health platforms. The title of Clause III(B) was also amended to read "Matters which are necessary for furtherance of the objects specified in Clause III(A)" from its prior wording. The filing confirms that core business activities in the pharmaceutical sector remain unchanged.
Impact on Investors
Investors will note that this alteration does not change the company's existing business or financial structure. The filing states explicitly that the principal business activities remain unchanged. The broader Object Clause now formally accommodates adjacent growth areas such as contract research, digital health, and gene therapy, which the filing presents as alignment with current and proposed activities rather than a declared new strategic pivot.
Shareholders will observe that the adoption of the new AOA under Table-F of Schedule I of the Companies Act, 2013 is a compliance-driven update. No dilution, change in promoter holding, or financial commitment is disclosed in connection with these amendments. The disclosed terms indicate this is a governance and regulatory alignment measure.
Sector / Market Context
India's pharmaceutical industry is one of the largest globally by volume, supplying over 20% of global generic medicines by volume according to data cited by the Ministry of Chemicals and Fertilizers. Regulatory alignment of constitutional documents with the Companies Act, 2013 has been an ongoing compliance priority for listed Indian pharma companies since the Act's implementation, with SEBI requiring timely disclosure of such changes under Regulation 30 of its Listing Obligations and Disclosure Requirements framework.